Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience
- First Online:
- 400 Downloads
To retrospectively evaluate the feasibility of arterial spin labeling (ASL) magnetic resonance imaging (MRI) for the assessment of vascularity of renal masses in patients with impaired renal function.
Between May 2007 and November 2008, 11/67 consecutive patients referred for MRI evaluation of a renal mass underwent unenhanced ASL-MRI due to moderate-to-severe chronic or acute renal failure. Mean blood flow in vascularised and non-vascularised lesions and the relation between blood flow and final diagnosis of malignancy were correlated with a 2-sided homogeneous variance t-test and the Fisher Exact Test, respectively. A p value <0.05 was considered statistically significant.
Seventeen renal lesions were evaluated in 11 patients (8 male; mean age = 70 years) (range 57–86). The median eGFR was 24 mL/min/1.73 m2 (range 7–39). The average blood flow of 11 renal masses interpreted as ASL-positive (134 +/− 85.7 mL/100 g/min) was higher than that of 6 renal masses interpreted as ASL-negative (20.5 +/− 8.1 mL/100 g/min)(p = 0.015). ASL-positivity correlated with malignancy (n = 3) or epithelial atypia (n = 1) at histopathology or progression at follow up (n = 7).
ASL detection of vascularity in renal masses in patients with impaired renal function is feasible and seems to indicate neoplasia although the technique requires further evaluation.
Arterial spin labeling may help to characterise renal masses in patients with renal failure
Detection of blood flow on ASL in a renal mass supports the presence of a neoplasm
Renal masses with high blood-flow levels on ASL seem to progress rapidly
KeywordsMagnetic resonance imaging Kidney neoplasms Perfusion Renal insufficiency Nephrogenic systemic fibrosis
- 5.American College of Radiology Committee on Drugs and Contrast Media. Manual on contrast media. Version 7, 2010. www.acr.org/…/quality_safety/contrast_manual/FullManual.aspx
- 6.European Medicines Agency. Questions and answers on the review of gadolinium contrast agents. July 1st, 2010. London UKGoogle Scholar